Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Immunovant Sciences GmbH
The total study duration per participant is approximately 61 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have documented diagnosis of SCLE or CCLE that has been confirmed by biopsy with or without systemic LE manifestations.
Have active CLE despite an adequate trial of conventional therapies.
Are positive for at least one autoantibody at Screening.
You may not be if
Have known or suspected drug-induced CLE anti-phospholipid disease, or neuropsychiatric SLE.
Have rapidly progressive nephritis.
Have current inflammatory skin disease other than SCLE/CCLE that, in the opinion of the Investigator, could interfere with the inflammatory skin assessments or confound the disease activity assessments.
Clareo Health | A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
